logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Human Immunodeficiency Virus I Infection

    FiltersReset Filters
    14 results

    • cabenuva

      (cabotegravir and rilpivirine)
      ViiV Healthcare Company
      Usage: CABENUVA is indicated for the treatment of HIV-1 in adults and adolescents (12 years and older, 35 kg+) as a complete regimen to replace current antiretroviral therapy in those who are virologically suppressed, with no history of treatment failure or known resistance to its components.

    • complera

      (emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate)
      Gilead Sciences, Inc.
      Usage: COMPLERA® is indicated for treating HIV-1 in adults and children (≥35 kg) as initial therapy for those with no treatment history and HIV-1 RNA ≤100,000 copies/mL, or to replace a stable regimen in virologically suppressed patients. Limitations include risk of virologic failure in those with higher baseline HIV-1 RNA.

    • delstrigo

      (doravirine, lamivudine, and tenofovir disoproxil fumarate)
      Merck Sharp & Dohme LLC
      Usage: DELSTRIGO® is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg, either as a complete regimen for those with no prior antiretroviral treatment or to replace the current regimen in patients who are virologically suppressed with no history of treatment failure.

    • evotaz

      (atazanavir and cobicistat)
      E.R. Squibb & Sons, L.L.C.
      Usage: EVOTAZ® is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents for adults and pediatric patients weighing at least 35 kg. Its use in treatment-experienced patients should be guided by baseline protease inhibitor resistance.

    • fuzeon

      (Enfuvirtide)
      Genentech, Inc.
      Usage: FUZEON® is indicated for the treatment of HIV-1 infection in treatment-experienced patients who show evidence of ongoing HIV-1 replication despite receiving antiretroviral therapy, in combination with other antiretroviral agents.

    • lamivudine

      (lamivudine oral)
      Chartwell RX, LLC
      Usage: Lamivudine oral solution is indicated in combination with other antiretroviral agents for treating HIV-1 infection. It is not intended for use in hepatitis B virus (HBV) treatment.

    • odefsey

      (emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide)
      Gilead Sciences, Inc.
      Usage: ODEFSEY is indicated for the treatment of HIV-1 infection in patients weighing at least 25 kg, either as initial therapy for those with no prior treatment history and HIV-1 RNA ≤ 100,000 copies/mL, or to replace a stable regimen in virologically suppressed patients.

    • pifeltro

      (doravirine)
      Merck Sharp & Dohme LLC
      Usage: PIFELTRO® is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥35 kg) in combination with other antiretroviral agents, either for those with no prior treatment history or to replace a stable regimen in virologically-suppressed patients without treatment failure history.

    • prezcobix

      (DARUNAVIR ETHANOLATE and COBICISTAT)
      Janssen Products LP
      Usage: PREZCOBIX is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents for both treatment-naïve and treatment-experienced adults and pediatric patients (weighing at least 40 kg) without specific darunavir resistance mutations.

    • prezista

      (darunavir)
      Janssen Products LP
      Usage: PREZISTA, when co-administered with ritonavir and other antiretroviral agents, is indicated for the treatment of HIV-1 infection in adults and pediatric patients aged 3 years and older.